Today’s Top Three in Pharma 012009

Will pharma sales forces drop (overall) by another 20% in the coming years? ZS Associates thinks yes. Interesting perspectives in this article.

FDA missing yet another drug review deadline (Takeda’s experimental gout drug). Question: if these pharma companies are paying additional fees to ensure that the FDA gives prompt reviews, why is there no accountability when FDA is chronically late?? Perhaps the FDA should undergo the sanctions that pharma companies receive for false claims…

DTC spending. Heading down.

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.